- Amplia Therapeutics (ATX) releases new data showing its AMP945 treatment returns similar efficacy results to the current standard of care for idiopathic pulmonary fibrosis
- New data from Amplia’s preclinical studies demonstrated AMP945 showed comparable activity on a mouse model to the current market leader in treatment, OFEV
- The study was designed as a more “demanding and meaningful” treatment model, compared to prevention models, which are routinely used
- The company says this new data provides significant encouragement to clinical investigators and patients in its planned clinical trials of AMP945 for this devastating disease
- Amplia Therapeutics is up 18.81 and a half per cent, trading at 13 cents at 12:48 pm AEST
Amplia Therapeutics (ATX) has released new data showing its AMP945 treatment returned similar efficacy results to the current standard of care for idiopathic pulmonary fibrosis.
New data from Amplia’s preclinical studies demonstrated the AMP945 focal adhesion kinase (FAK) inhibitor showed comparable activity on a mouse model to the current market leader in treatment, OFEV.
The studies were performed by an independent contract research organisation that specialises in fibrosis disease models.
The study was designed as a more “demanding and meaningful” treatment model, compared to prevention models, which are routinely used. The mice in the trial were challenged with saline only or bleomycin, and lung fibrosis was allowed to develop for a week.
Mice that had been challenged with bleomycin were then randomised into four groups and treated orally with an inactive drug delivery vehicle, AMP945, OFEV, or a combination of AMP945 and OFEV for 14 days.
In the study arm combining treatment with AMP945 and OFEV, there was no detectable increase in efficacy.
The company said there are two current pharmaceutical standards of care for idiopathic pulmonary fibrosis (IPF). However, both drugs have significant side-effect profiles which limit their utility.
As such, there is a considerable effort underway to find more tolerable and effective treatments for this debilitating and deadly disease.
John Lambert, Amplia’s CEO and Managing Director, said Amplia’s AMP945 had an excellent safety and tolerability profile at doses that resulted in measurable inhibition of its intended target.
“These new results reconfirm the efficacy of AMP945 in the industry-standard preclinical IPF model and show that, in a head-to-head comparison, the activity of AMP945 is comparable to the current market leader, OFEV,” Dr Lambert said.
“This information should provide significant encouragement to clinical investigators and patients in our planned clinical trials of AMP945 in this devastating disease.”
Amplia Therapeutics was up 18.81 and a half per cent, trading at 13 cents at 12:48 pm AEST.